Fish Oil to Prevent Intimal Hyperplasia and Access Thrombosis

Diskin, Charles J.; Thomas, Clément; Zellner, C.P.; Lock, Stephen; Tanja, J.

doi:10.1159/000186022

Cited by 30 publications

(31 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four of eight studies found a reduction in platelet counts (54,56,57,66), although only one dropped below the normative range (54). No effect on the prothrombin or partial thromboplastin times was documented (53,70,76). Although reductions in fibrinogen levels were noted in two uncontrolled cohorts (63,64), this finding was not replicated under controlled conditions (75).…”

Section: Hematologicmentioning

confidence: 99%

“…Overall, there are no clear effects of fish oil-derived omega-3 fatty acids on platelet aggregation, blood viscosity, red blood cell survival, and bleeding times, even at high doses (1.7 to 7.6 g/d) (52)(53)(54)(55)(56)58,69,70,(75)(76)(77). Four of eight studies found a reduction in platelet counts (54,56,57,66), although only one dropped below the normative range (54).…”

Section: Hematologicmentioning

confidence: 99%

“…Most adverse effects involved gastrointestinal complaints such as nausea, vomiting, diarrhea, dysgeusia, and abdominal discomfort. Serious bleeding complications were isolated to a single patient in one uncontrolled study (76).…”

Section: Adverse Effectsmentioning

confidence: 99%

See 2 more Smart Citations

Review of the Effects of Omega-3 Supplementation in Dialysis Patients

Friedman

Moe²

2006

Clinical Journal of the American Society of Nephrology

117

View full text Add to dashboard Cite

Chronic dialysis patients experience a host of conditions that limit quality and length of life, and recent therapeutic strategies have had only modest success in ameliorating many of these problems. By mediating cell membrane function and structure and the synthesis of lipid mediators such as eicosanoids, omega-3 fatty acids may offer dialysis patients a host of therapeutic benefits. Omega-3 fatty acids are derived primarily from dietary sources, and cold-water fish is the main source of eicosapentanoic and docosahexanoic acids, the two major bioactive omega-3 fatty acids. Studies of omega-3 supplementation in dialysis patients describe salutary effects on triglyceride levels, dialysis access patency, and perhaps uremic pruritus and oxidative stress. In contrast, the putative hematologic, antihypertensive, anti-inflammatory, and antiarrhythmic effects are not as well documented. Adverse effects generally have been limited to gastrointestinal complaints. Unfortunately, the preponderance of published studies are characterized by suboptimal study design, small sample sizes, supraphysiologic omega-3 doses that may be difficult to consume for extended periods, little long-term follow-up, and a lack of confirmation of compliance. Not surprising, the 2005 National Kidney Foundation Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients recommend further research in this field. In summary, although preliminary data suggest that omega-3 fatty acids may have clinical benefits, formal recommendations encouraging omega-3 supplementation of dialysis patients are premature until long-term and adverse effects are better defined.

show abstract

Section: Hematologicmentioning

confidence: 99%

Section: Hematologicmentioning

confidence: 99%

See 1 more Smart Citation

Review of the Effects of Omega-3 Supplementation in Dialysis Patients

Friedman

Moe²

2006

Clinical Journal of the American Society of Nephrology

117

View full text Add to dashboard Cite

show abstract

“…We have previously reported the benefits of ω–3 fatty acids in a prospective study [1]. We have also recently reviewed the current hypotheses regarding the pathophysiology of vascular access thrombosis after which we outlined other potential avenues of pharmacologic intervention in an effort to alter the course of that pathophysiology and thereby improve long-term vascular patency [2].…”

Section: Introductionmentioning

confidence: 99%

“…We have already reported the practical and theoretical benefit of ω–3 fatty acids [1]. Now we feel that ACE inhibitors, alkylating agents, Coumadin, pentoxifylline and calcium channel blockers have clinical potential as well as theoretical promise.…”

Section: Introductionmentioning

confidence: 99%

An Analysis of the Effect of Routine Medications on Hemodialysis Vascular Access Survival

Diskin¹,

Stokes²,

Thomas³

et al. 1998

Nephron

View full text Add to dashboard Cite

Omega 3 fatty acids for prevention and treatment of cardiovascular disease

Hooper

2004

Cochrane Database of Systematic Reviews

191

143

View full text Add to dashboard Cite

Background It has been suggested that omega 3 (W3, n-3 or omega-3) fats from oily fish and plants are beneficial to health. Objectives To assess whether dietary or supplemental omega 3 fatty acids alter total mortality, cardiovascular events or cancers using both RCT and cohort studies. Search methods Five databases including CENTRAL, MEDLINE and EMBASE were searched to February 2002. No language restrictions were applied. Bibliographies were checked and authors contacted. Selection criteria RCTs were included where omega 3 intake or advice was randomly allocated and unconfounded, and study duration was at least six months. Cohorts were included where a cohort was followed up for at least six months and omega 3 intake estimated. Data collection and analysis Studies were assessed for inclusion, data extracted and quality assessed independently in duplicate. Random effects meta-analysis was performed separately for RCT and cohort data. Main results Forty eight randomised controlled trials (36,913 participants) and 41 cohort analyses were included. Pooled trial results did not show a reduction in the risk of total mortality or combined cardiovascular events in those taking additional omega 3 fats (with significant statistical heterogeneity). Sensitivity analysis, retaining only studies at low risk of bias, reduced heterogeneity and again suggested no significant effect of omega 3 fats. Restricting analysis to trials increasing fish-based omega 3 fats, or those increasing short chain omega 3s, did not suggest significant effects on mortality or cardiovascular events in either group. Subgroup analysis by dietary advice or supplementation, baseline risk of CVD or omega 3 dose suggested no clear effects of these factors on primary outcomes. Neither RCTs nor cohorts suggested increased relative risk of cancers with higher omega 3 intake but estimates were imprecise so a clinically important effect could not be excluded. Authors’ conclusions It is not clear that dietary or supplemental omega 3 fats alter total mortality, combined cardiovascular events or cancers in people with, or at high risk of, cardiovascular disease or in the general population. There is no evidence we should advise people to stop taking rich sources of omega 3 fats, but further high quality trials are needed to confirm suggestions of a protective effect of omega 3 fats on cardiovascular health. There is no clear evidence that omega 3 fats differ in effectiveness according to fish or plant sources, dietary or supplemental sources, dose or presence of placebo.

show abstract

Fish Oil to Prevent Intimal Hyperplasia and Access Thrombosis

Cited by 30 publications

References 10 publications

Review of the Effects of Omega-3 Supplementation in Dialysis Patients

Review of the Effects of Omega-3 Supplementation in Dialysis Patients

An Analysis of the Effect of Routine Medications on Hemodialysis Vascular Access Survival

Omega 3 fatty acids for prevention and treatment of cardiovascular disease

Contact Info

Product

Resources

About